#121801
#121802
Re: Farmas USA
EXEL (+20%) BMY
Bristol Myers Squibb and Exelixis Announce Positive Topline Results from Pivotal Phase 3 CheckMate -9ER Trial Evaluating Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) in Previously Untreated Advanced Renal Cell Carcinoma
https://ir.exelixis.com/news-releases/news-release-details/bristol-myers-squibb-and-exelixis-announce-positive-topline
Bristol Myers Squibb and Exelixis Announce Positive Topline Results from Pivotal Phase 3 CheckMate -9ER Trial Evaluating Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) in Previously Untreated Advanced Renal Cell Carcinoma
https://ir.exelixis.com/news-releases/news-release-details/bristol-myers-squibb-and-exelixis-announce-positive-topline
#121803
Re: Farmas USA
Gilead: New Remdesivir Data Set Up A Potential Short Trade
On Thursday, April 16, STAT put up an article by Adam Feuerstein and Matthew Herper
- These details weren't officially from GILD via press release ..
-- I'm inclined to trust the source here even if that video isn't available, but I am not inclined to believe the numbers offer proof of efficacy for remdesivir.
-- Lastly, anyone shorting GILD is exposed to readouts from other remdesivir studies, not just the US severe COVID-19 study.
-- I think that data from the Chinese mild/moderate study won't show anything as too few patients
-- What is going on with the Chinese trials?
- These details weren't officially from GILD via press release ..
-- I'm inclined to trust the source here even if that video isn't available, but I am not inclined to believe the numbers offer proof of efficacy for remdesivir.
-- Lastly, anyone shorting GILD is exposed to readouts from other remdesivir studies, not just the US severe COVID-19 study.
-- I think that data from the Chinese mild/moderate study won't show anything as too few patients
-- What is going on with the Chinese trials?
Summary
An "early peek" at data from GILD's US/international study of remdesivir in COVID-19 has the market excited, GILD is trading up.I don't think the numbers are exciting.
-We need to wait for results from these trials.Chinese studies of remdesivir have stalled and the mild/moderate COVID-19 study of remdesivir may not have enrolled many patients at all.
-We need to wait for results from these trials.Chinese studies of remdesivir have stalled and the mild/moderate COVID-19 study of remdesivir may not have enrolled many patients at all.
#121804
Re: Farmas USA
#121805
Re: Farmas USA
Nvax
Jode con esta...
Bueno a mi cuanto mas arriba vaya mejor. Ya casi duplico los 4K€.En 23 exactamente. Asik no me voy a quejar. Este año esta me ha dado bastante de lo que me quito. No todo pq eso era demasiado pero un buen cacho si.
Que os parece, macrodilucion pronto?
Patapum con buenos resultados de vacuna covid hasta esa zona de 40, antiguas 2$?
Jode con esta...
Bueno a mi cuanto mas arriba vaya mejor. Ya casi duplico los 4K€.En 23 exactamente. Asik no me voy a quejar. Este año esta me ha dado bastante de lo que me quito. No todo pq eso era demasiado pero un buen cacho si.
Que os parece, macrodilucion pronto?
Patapum con buenos resultados de vacuna covid hasta esa zona de 40, antiguas 2$?
#121806
Re: Farmas USA
#121807
Re: Farmas USA
#121808